Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue: +2,356.5%
EPS: +46.3%
Free cash flow: −6.73%
Total debt: −83.9%

Quarter to September 2026, against a year earlier

54.93 0.62 −1.12%

Follow CYTK

Alert me

Market cap: $7.7B
P/E: 0.0×
Fwd P/E: −10.3×
Dividend yield: —
F-score: 2/9
Altman Z: −1.98
Beneish M: −0.44
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Cytokinetics, Incorporated (CYTK) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Cytokinetics, Incorporated (CYTK) trades at a P/S ratio of 64.4×. Over the past ten years it has ranged from 3.8× (January 2017) to 2,143× (November 2024); the current reading is higher than 69% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/CYTK/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Cytokinetics, Incorporated P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/CYTK/metrics/ps-ratio">Cytokinetics, Incorporated (CYTK) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	86.7×	(69.60%)
FY2024	285×	(73.56%)
FY2023	1,078×	2,460.27%
FY2022	42.1×	(15.36%)
FY2021	49.8×	107.19%
FY2020	24.0×	5.63%
FY2019	22.7×	108.24%
FY2018	10.9×	(66.24%)
FY2017	32.3×	594.72%
FY2016	4.7×	(67.14%)

Period	P/S ratio	Change
Sep 2026	76.8×	(53.79%)
Jun 2026	166×	116.56%
Mar 2026	76.8×	(11.42%)
Dec 2025	86.7×	14.64%
43 more quarters	Free account

Against its own ten years

Low 3.8× High 2,143×

Ten-year median 30.0×

Current reading's percentile 66

Company	P/S ratio
CAI Caris Life Sciences,�Inc. compare	7.1×
CORT Corcept Therapeutics Incorporated compare	8.0×
MDGL Madrigal Pharmaceuticals, Inc. compare	8.2×
ARWR Arrowhead Pharmaceuticals, Inc. compare	12.3×
TWST Twist Bioscience Corporation compare	17.6×
KRYS Krystal Biotech, Inc. compare	18.9×
PTGX Protagonist Therapeutics, Inc. compare	31.7×
CYTK Cytokinetics, Incorporated	64.4×
SYRE Spyre Therapeutics, Inc. compare	8,160×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Cytokinetics, Incorporated (CYTK) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on CYTK

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on CYTK

Stockrow Weekly